Sign in
CompletedNo phase

Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology Lens

Key facts

Who runs it
Bausch & Lomb Incorporated
Where
Bloomfield, Edina, Jacksonville, Kirkland, Nashville, and St Louis, United StatesSee the 6 sites
Trial code
Status
Completed
People taking part
90 people enrolled
Started
11 Jul 2023
Ended
27 Jun 2024
Type of study
Interventional
Treatments tested
  • orthokeratology lens
Record updated
24 August 2025

Who can take part

Age
12 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Be 12 years or older on the date the Informed Consent Form (ICF) is signed and, as subject or parent or legal guardian of a minor subject, have capacity to read, understand and provide written voluntary informed consent on the IRB-approved ICF and provide authorization as appropriate for local privacy regulations
  • Be orthokeratology lens naïve
  • Spherical refractive error between plano and -5.00D
  • Astigmatism no greater than 1.50D
  • Corneal topography sagittal height differential of ≥ 30 microns between the two main meridians (flat and steep) at an 8mm chord
  • Has keratometric readings from 39.00 to 48.00D
  • Has a clear and undistorted Mire Reflex
  • Be willing and able to comply with all treatment and follow-up study visits and procedures
  • Must be willing to refrain from wearing habitual soft contact lenses during the study period
  • Subjects must be correctable through spherocylindrical refraction to 42 letters (0.1 logMAR) or better (distance, high contrast) in each eye

Who cannot take part

  • Prior eyelid, strabismus, intraocular, or refractive surgery
  • Subjects using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance
  • Subjects participating in any drug or device clinical investigation within 2 weeks prior to entry into this study (Screening Visit) and/or planning to do so during the period of study participation
  • Subjects with any systemic disease currently affecting ocular health or in the Investigator's opinion may have an effect on ocular health during the course of the study
  • A known allergy to fluorescein, benoxinate, or proparacaine
  • A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or recurrent ocular infections
  • Subjects with an active ocular disease or who are using any ocular medication
  • Subject is considered by the Investigator, to not be a suitable candidate for participation or it is not in the best interest of the subject to participate in the study
  • Subjects who have worn rigid gas permeable (RGP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last three months
  • Keratoconus or an irregular cornea
  • Subjects with any Grade 2 or greater finding during the slit lamp examination. Subjects with corneal infiltrates, of ANY GRADE, are NOT eligible. Refer to Appendix B: Methods of Clinical Evaluation
  • Subjects with any "Present" finding during the slit lamp examination that, in the Investigator's judgement, interferes with contact lens wear. Refer to Appendix B: Methods of Clinical evaluation
  • Subjects with any scar or neovascularization within the central 6mm of the cornea. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgement, does not interfere with contact lens wear, are eligible for this study
  • Subjects who are amblyopic
  • Immediate family or close relative is a member of the office staff, including the Investigator(s)
  • Females of childbearing potential (those who are not surgically sterilized or postmenopausal) if they meet any one of the following:; They are currently pregnant; They plan to become pregnant during the study; They are breastfeeding

Where in United States

  • Birmingham Vision Care P.C.Bloomfield, United States
  • Cornea and Contact Lens Institute of MinnesotaEdina, United States
  • Levenson Eye AssociatesJacksonville, United States
  • Speciality Eyecare GroupKirkland, United States
  • Optometric Physicians of Middle TennesseeNashville, United States
  • The Koetting AssociatesSt Louis, United States

About the trial

What the trial wants to find out

The objective of this orthokeratology study is to evaluate the safety and effectiveness of the Arise Orthokeratology Lens with non-spherical posterior peripheral curves

The group in the trial

  • Safety and effectiveness of the Arise Orthokeratology LensTreatment being tested

    Treatment effect of overnight orthokeratology over a 3-month period

    Treatment: orthokeratology lens

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study to Evaluate Safety and Effectiveness of the Boston Orthokeratology (Oprifocon A) Shaping Lens in the Arise Orthokeratology Lens Design With Non-spherical Posterior Peripheral Curves
Record updated
24 August 2025